HTL0039732 in Participants With Advanced Solid Tumours

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.

Trial Details

NCT ID
NCT05944237
Phase
PHASE1 / PHASE2
Sponsor
Cancer Research UK
Status
RECRUITING
Cancer Type
Pancreatic Neuroendocrine Pancreatic Cancer
Interventions
  • HTL0039732 Capsules
  • HTL0039732 Capsules and atezolizumab infusion
Locations (sample)
  • Cambridge, United Kingdom|52.2,0.11667
  • Cardiff, United Kingdom|51.48,-3.18
  • Liverpool, United Kingdom|53.41058,-2.97794
  • London, United Kingdom|51.50853,-0.12574
  • Manchester, United Kingdom|53.48095,-2.23743

Key Eligibility Criteria

  • Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product administration and follow-up.
  • Phase 1, dose escalation phase
  • Part A (HTL0039732 monotherapy):
  • Histologically or cytologically proven advanced solid tumour, refractory to conventional treatment, or for which no further conventional therapy is…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Neuroendocrine Pancreatic Cancer Trials on Trialify →